Trending Now - Novo Nordisk Seeks Deals and Boosts Sales With Wegovy Success

WHO:

CNBC - Mike Doustdar, CEO of Novo Nordisk

Bloomberg - Mike Doustdar, CEO of Novo Nordisk

WHAT:

CNBC - Novo Nordisk is actively seeking deals and acquisitions to enhance its pipeline.

Bloomberg - Novo Nordisk's Wegovy obesity pill fueled sales in the first quarter.

Bloomberg - Novo Nordisk raised its forecast for profit and sales declines to a maximum of 12% for the year, an improvement from the previously expected 13%.

WHERE:

Bloomberg - Copenhagen, Denmark (location of Novo Nordisk)

WHEN:

Bloomberg - The company anticipates the worst drop for both profit and sales will be 12% for the year.

WHY:

CNBC - Novo Nordisk aims to help hundreds of millions of patients and believes it needs the broadest pipeline to achieve this goal.

Bloomberg - Novo Nordisk is "very optimistic" about Wegovy despite competition from Eli Lilly and does not anticipate any price reductions.

HOW:

CNBC - Novo Nordisk is engaging in business development talks and acquisitions to find complementary assets.

(UPDATED May 6, 2026 19:25 UTC)

Novo Nordisk, based in Copenhagen, Denmark, is actively pursuing deals and acquisitions to enhance its pipeline, as CEO Mike Doustdar announced. The company reported strong sales from its Wegovy obesity pill in the first quarter and has raised its forecast for profit and sales declines to a maximum of 12% for the year, an improvement from the previously expected 13%. Novo Nordisk remains optimistic about Wegovy's prospects despite competition from Eli Lilly and is engaging in business development talks to find complementary assets to help serve hundreds of millions of patients.